Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
First patients enrolled in phase II and IV breast cancer studies for Modrenal
October 20th, 2005
Bioenvision (BIVN) announced that the first seven patients had been enrolled in a phase IV clinical study of Modrenal (trilostane) in postmenopausal women with advanced breast cancer. The trial has been designed to evaluate the efficacy of Modrenal in patients who have failed prior endocrine therapy with the new generation aromatase inhibitors. The study will be conducted in 9 leading U.K. centers and will enroll up to an additional 54 patients. "We are delighted with the rapid recruitment we have seen in the first month of the study and we expect to complete enrollment within a year," said Hugh Griffith, Bioenvision's COO. ...
Source: Women's Health Weekly (2005-10-20)
|
